Davunetide slows progression of rare brain disease in women
Jerusalem (ANTARA) - Researchers from Israel have found that an existing drug can slow the progression of a rare and fatal brain disease in women, according to Tel Aviv University in a statement released on Sunday (26/7).
In their study published in the journal Molecular Psychiatry by Nature, the research team re-examined data from an international clinical trial involving more than 300 patients with progressive supranuclear palsy, a rare and incurable brain disease that affects movement, balance and the ability to think.
Although the initial study concluded that Davunetide, a drug targeting a group of diseases known as tauopathies, was proven safe but not very effective, the new analysis found different results when analysing female and male patient groups separately.
Women patients who received the drug therapy showed a significant slowing in disease progression. This benefit was not observed in male patients.
The therapy helped women patients maintain essential daily life functions, including balance, hand coordination, and routine tasks such as using cutlery, buttoning clothes and bathing. They also showed better results in memory, language and other cognitive tests.
The researchers said the findings could advance research into Alzheimer’s and related brain disorders, whilst also underscoring the need to develop treatments that take account of biological differences between the sexes.
Source: jawawa.id (https://jawawa.id/newsitem/davunetide-slows-progression-of-rare-brain-disease-in-women-1785146222)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5667753/davunetide-perlambat-perkembangan-penyakit-otak-langka-pada-wanita), translated from Indonesian